TRIAL DETAIL

Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody

Drug:
Trial Name:
Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody
NCT#:
Conditions:
Solid Tumors
Status:
Active, not recruiting
Phase:
1
Start Date 08/19/2014
Age of Trial (yrs) 9.7
Treatment Phase:
Gleevec-resistant
Drug Category:
CD47 inhibitor
Strategy:
Immunotherapy
Trial Type:
GIST not specified. GIST patient enrollment unknown.
Other Protocol IDs:
VAR0113
Sponsor:
Forty Seven, Inc.
Patient Contact:
Chris Takimoto, MD info@fortyseveninc.com
Contact email:
Contact Phone:
Randomized:
IV or Oral:
Intravenous
Trial Notes:
Detailed Description:
This is a first-in-human, first-in-class, escalating dose trial of an antibody that inhibits an anti-apoptotic signal in human macrophages. The major aims of the study are to define the safety profile of this new drug, and to determine a recommended dose and schedule for potential additional trials.

Trial Links
 

Trial Results

Drug Information
CureSearch: Developing CD47 Antibody Therapy
 
NCI Drug Dictionary
 
Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential.
 
Forty Seven, Inc. science of CD47 inhibition
 

Trial Sites

Name
Address
City
State
Zip
Country
Palo Alto
CA
94304
USA
1275 York Ave
New York
NY
10065
USA
4319 Medical Dr.
San Antonio
TX
78229
USA
Grand Rapids
MI
49503
USA